ArticleCancer research2014
Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells.
Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Differential Effects of High-Fiber and Low-Fiber Diets on Antitumor Immunity and Colon Tumor Progression in a Murine Model.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Mast cells: key players in digestive system tumors and their interactions with immune cells.Cell death discovery · 2025Review
- Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning.Scientific reports · 2024Article
- Advances in engineering and delivery strategies for cytokine immunotherapy.Expert opinion on drug delivery · 2023Article
- Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis.Inflammatory bowel diseases · 2022Article
- Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry.Mucosal immunology · 2022Review
- Tissue Resident Foxp3Frontiers in immunology · 2022Review
- Oral drug delivery for immunoengineering.Bioengineering & translational medicine · 2022Review
- Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2020Article
- Review
- Role of Inflammation in Pathophysiology of Colonic Disease: An Update.International journal of molecular sciences · 2020Review
- In vivo tracking of orally-administered particles within the gastrointestinal tract of murine models using multispectral optoacoustic tomography.Photoacoustics · 2019Article
- Bilirubin Attenuates ER Stress-Mediated Inflammation, Escalates Apoptosis and Reduces Proliferation in the LS174T Colonic Epithelial Cell Line.International journal of medical sciences · 2019Article
- Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Inflammation and Colorectal Cancer.Current colorectal cancer reports · 2017Article
- RORγt expression in TClinical and experimental immunology · 2017Article
- Cytokine-Induced Modulation of Colorectal Cancer.Frontiers in oncology · 2016Review
- Synergy of Transforming Growth Factor Beta 1 and All Trans Retinoic Acid in the Treatment of Inflammatory Bowel Disease: Role of Regulatory T cells.Journal of gastroenterology, pancreatology & liver disorders · 2016Article
- Nasopharyngeal cancer-derived microRNA-21 promotes immune suppressive B cells.Cellular & molecular immunology · 2015Article
- Inflammation-associated genes: risks and benefits to Foxp3+ regulatory T-cell function.Immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model of spontaneous gastrointestinal polyposis, that site-specific uptake of orally administered IL10 microparticles ameliorates local and systemic disease to enhance survival. Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutralization of disease-promoting FoxP3(+)RoRγt(+)IL17(+) pathogenic T-regulatory cells (pgTreg), with a concomitant restoration of FoxP3(+)RoRγt(-)IL17(-) conventional T-regulatory cells (Treg). These findings provide a proof-of-principle for the ability of an oral biologic to restore immune homeostasis at the intestinal surface. Furthermore, they implicate local manipulation of IL10 as a tractable therapeutic strategy to address the inflammatory sequelae associated with mucosal premalignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.